Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 07, 2005. The report details changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) resulting from share purchase plans, dividend reinvestments, and trust distributions.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on transactional details regarding director shareholdings.
- Share Purchase Price (ShareReward Plan): £12.37 per Ordinary Share
- Share Purchase Price (Single Company ISA): £12.39 per Ordinary Share
- Dividend Reinvestment Price (ADRs): $46.41 per share
Material Changes
The filing reports specific changes in director interests occurring on January 06, 2005, and notified on January 07, 2005:
- Mr. J D Coombe: Acquired 6 Ordinary Shares via the Dividend Reinvestment element of the ShareReward Plan and 3 Ordinary Shares via a Single Company ISA.
- Mrs. G A Coombe: Acquired 3 Ordinary Shares via a Single Company ISA.
- Sir Peter Job: Acquired 6 Ordinary Shares via a Single Company ISA.
- Dr. J P Garnier: Increased interest in Ordinary Share ADRs by 294.057 units via the Executive Supplemental Savings Plan.
- Dr. T Yamada: Increased interest in Ordinary Share ADRs by 189.209 units via the Executive Supplemental Savings Plan.
- GSK Trust Distribution: The GlaxoSmithKline Employee Trust transferred 15,321 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory disclosure of director share transactions.
Investor Verification Checklist
- Verify the total number of shares held by directors post-transaction against the company's latest insider ownership reports.
- Confirm the dividend amount per share implied by the reinvestment prices (£12.37, £12.39, and $46.41) against the official dividend announcement.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting schedule for the 15,321 shares distributed from the GSK Trust.
- Check for any subsequent filings regarding the Executive Supplemental Savings Plan to track the cumulative ADR holdings of Dr. Garnier and Dr. Yamada.